The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The most read stories this past month detailed the passing of Dimitrios Karmpaliotis and news on Evoque and COVID-19.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...